Acid-detoxified Inaba lipopolysaccharide (pmLPS) is a superior cholera conjugate vaccine immunogen than hydrazine-detoxified lipopolysaccharide and induces vibriocidal and protective antibodies

Pathogens and Disease

Volumn 67, Issue 2, 2013, Pages 136-158

  Grandjean, Cyrille ^a,b   Wade, Terri K ^c   Ropartz, David ^d   Ernst, Logan ^e   Wade, William F ^c  

^a Faculté des Sciences et Techniques   (France)

^b UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

^d INRA   (France)

^e KENYON COLLEGE   (United States)

Author keywords

Cholera; Conjugate vaccine; Lipopolysaccharide; Vibrio cholerae

Indexed keywords

ACID DETOXIFIED INABA LIPOPOLYSACCHARIDE; CARRIER PROTEIN; CHOLERA VACCINE; HYDRAZINE DETOXIFIED LIPOPOLYSACCHARIDE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LIPID A; LIPOPOLYSACCHARIDE; SUGAR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CHOLERA; CONJUGATE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; MICROTITER PLATE ASSAY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEROLOGY;

ACETIC ACID; ANIMALS; ANTIBODIES, BACTERIAL; CHOLERA; CHOLERA VACCINES; FEMALE; HUMANS; HYDRAZINES; LIPOPOLYSACCHARIDES; MICE; VACCINES, CONJUGATE; VIBRIO CHOLERAE;

EID: 84878118683     PISSN: None     EISSN: 2049632X     Source Type: Journal    
DOI: 10.1111/2049-632X.12022     Document Type: Article

References (56)

1. Ahmed A, Bhattacharjee AK & Mosley WH (1970) Characteristics of the serum vibriocidal and agglutinating antibodies in cholera cases and in normal residents of the endemic and non-endemic cholera areas. J Immunol 105: 431-441.
2. Ahmed F, André-Leroux G, Haouz A, Boutonnier A, Delepierre M, Qadri F, Nato F, Fournier JM & Alzari PM (2008) Crystal structure of a monoclonal antibody directed against an antigenic determinant common to Ogawa and Inaba serotypes of Vibrio cholerae O1. Proteins 70: 284-288.
3. Benenson AS, Joseph PR & Oseasohn RO (1968a) Cholera vaccine field trials in East Pakistan: 1. Reaction and antigenicity studies. Bull World Health Organ 38: 347-357.
4. Benenson AS, Mosley WH, Fahimuddin M & Oseasohn RO (1968b) Cholera vaccine field trials in East Pakistan: 2. Effectiveness in the field. Bull World Health Organ 38: 359-372.
5. Borrow R, Dagan R, Zepp F, Hallander H & Poolman J (2011) Glycoconjugate vaccines and immune interactions, and implications for vaccination schedules. Expert Rev Vaccines 10: 1621-1631.
6. Boutonnier A, Dassy B, Dumenil R, Guenole A, Ratsitorahina M, Migliani R & Fournier JM (2003) A simple and convenient microtiter plate assay for the detection of bactericidal antibodies to Vibrio cholerae O1 and Vibrio cholerae O139. J Microbiol Methods 55: 745-753.
7. Buchanan RM, Briles DE, Arulanandam BP, Westerink MA, Raeder RH & Metzger DW (2001) IL-12-mediated increases in protection elicited by pneumococcal and meningococcal conjugate vaccines. Vaccine 19: 2020-2028.
8. Buskas T, Li Y & Boons GJ (2004) The immunogenicity of the tumor-associated antigen Lewis(y) may be suppressed by a bifunctional cross-linker required for coupling to a carrier protein. Chemistry 10: 3517-3524.
9. Cabrera O, Cuello M, Soto CR, Martínez ME, del Campo JM, Pérez O, Infante JF & Sierra G (2006) New method for obtaining conjugated vaccines. Vaccine 2: S2-76-8.
10. Chatterjee SN & Chaudhuri K (2003) Lipopolysaccharides of Vibrio cholerae. I. Physical and chemical characterization. Biochim Biophys Acta 1639: 65-79.
11. Chernyak A, Kondo S, Wade TK, Meeks MD, Alzari PM, Fournier JM, Taylor RK, Kovac P & Wade WF (2002) Induction of protective immunity by synthetic Vibrio cholerae hexasaccharide derived from V. cholerae O1 Ogawa lipopolysaccharide bound to a protein carrier. J Infect Dis 185: 950-962.
12. Costantino P, Rappuoli R & Berti F (2011) The design of semi-synthetic and synthetic glycoconjugate vaccines. Expert Opin Drug Discov 6: 1045-1066.
13. Deen JL, von Seidlein L, Sur D, Agtini M, Lucas ME, Lopez AL, Kim DR, Ali M & Clemens JD (2008) The high burden of cholera in children: comparison of incidence from endemic areas in Asia and Africa. PLoS Negl Trop 2: e173.
14. Desai SN & Clemens JD (2012) An overview of cholera vaccines and their public health implications. Curr Opin Pediatr 24: 85-91.
15. Glass RI, Svennerholm AM, Khan MR, Huda S, Huq MI & Holmgren J (1985) Seroepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection. J Infect Dis 151: 236-242.
16. Grandjean C, Boutonnier A, Guerreiro C, Fournier JM & Mulard LA (2005) On the preparation of carbohydrate-protein conjugates using the traceless Staudinger ligation. J Org Chem 70: 7123-7132.
17. Grandjean C, Boutonnier A, Dassy B, Fournier JM & Mulard LA (2009) Investigation towards bivalent chemically defined glycoconjugate immunogens prepared from acid-detoxified lipopolysaccharide of Vibrio cholerae O1, serotype Inaba. Glycoconj J 26: 41-55.
18. Gupta RK, Szu SC, Finkelstein RA & Robbins JB (1992) Synthesis, characterization, and some immunological properties of conjugates composed of the detoxified lipopolysaccharide of Vibrio cholerae O1 serotype Inaba bound to cholera toxin. Infect Immun 60: 3201-3208.
19. Gupta RK, Egan W, Bryla DA, Robbins JB & Szu SC (1995) Comparative immunogenicity of conjugates composed of Escherichia coli O111 O-specific polysaccharide, prepared by treatment with acetic acid or hydrazine, bound to tetanus toxoid by two synthetic schemes. Infect Immun 63: 2805-2810.
20. Gupta RK, Taylor DN, Bryla DA, Robbins JB & Szu SC (1998) Phase 1 evaluation of Vibrio cholerae O1, serotype Inaba, polysaccharide-cholera toxin conjugates in adult volunteers. Infect Immun 66: 3095-3099.
21. Harris JB, LaRocque RC, Qadri F, Ryan ET & Calderwood SB (2012) Cholera. Lancet 379: 2466-2476.
22. Hisatsune K, Kondo S, Isshiki Y, Iguchi T & Haishima Y (1993) Occurrence of 2-O-methyl-N523 (3-deoxy-L-glycero-tetronyl)-D-perosamine (4-amino-4, 6-dideoxy-d-manno-pyranose) in lipopolysaccharide from Ogawa but not from Inaba O forms of O1 Vibrio cholerae. Biochem Biophys Res Commun 190: 302-307.
23. Hisatsune K, Kondo S, Iguchi T, Ito T & Hiramatsu K (1996) Lipopolysaccharides of Escherichia coli K12 strains that express cloned genes for the Ogawa and Inaba antigens of Vibrio cholerae O1: identification of O-antigenic factors. Microbiol Immunol 40: 621-626.
24. Iwanaga M, Yamamoto K, Higa N, Ichinose Y, Nakasone N & Tanabe M (1986) Culture conditions for stimulating cholera toxin production by Vibrio cholerae O1 El Tor. Microbiol Immunol 30: 1075-1083.
25. Jones C (2005) Vaccines based on the cell surface carbohydrates of pathogenic bacteria. An Acad Bras Cienc 77: 293-324.
26. Kabir S (1987) Preparation and immunogenicity of a bivalent cell-surface protein-polysaccharide conjugate of Vibrio cholerae. J Med Microbiol 23: 9-18.
27. Khan MU, Barua DK, Begum T & Shahidullah M (1987) Vibriocidal titre in cholera cases and contacts: its value in assessing endemicity of or susceptibility to cholera. Trop Geogr Med 39: 271-275.
28. Kirn TJ & Taylor RK (2005) TcpF is a soluble colonization factor and protective antigen secreted by El Tor and classical O1 and O139 Vibrio cholerae serogroups. Infect Immun 73: 4461-4470.
29. Kirn TJ, Jude BA & Taylor RK (2009) A colonization factor links Vibrio cholerae environmental survival and human infection. Nature 438: 863-866.
30. Leung DT, Rahman MA, Mohasin M et al. (2011) A comparison of memory B cell, antibody secreting cell, and plasma antibody responses in young children, older children, and adults with infection caused by Vibrio cholerae O1 El Tor Ogawa in Bangladesh. Clin Vaccine Immunol 18: 1317-1325.
31. Meeks MD, Saksena R, Ma X, Wade TK, Taylor RK, Kovac P & Wade WF (2004) Synthetic fragments of Vibrio cholerae O1 Inaba O-specific polysaccharide bound to a protein carrier are immunogenic in mice but do not induce protective antibodies. Infect Immun 72: 4090-4101.
32. Mosley WH, Woodward WE, Aziz KM, Rahman AS, Chowdhury AK, Ahmed A & Feeley JC (1970) The 1968-1969 cholera-vaccine field trial in rural East Pakistan. Effectiveness of monovalent Ogawa and Inaba vaccines and a purified Inaba antigen, with comparative results of serological and animal protection tests. J Infect Dis 121: 1-9.
33. Muse M, Grandjean C, Wade TK & Wade WF (2012) A one dose experimental cholera vaccine. FEMS Immunol Med Microbiol 66: 98-115.
34. Oliver AM, Martin F, Gartland GL, Carter RH & Kearney JF (1997) Marginal zone B cells exhibit unique activation, proliferative and immunoglobulin secretory responses. Eur J Immunol 27: 2366-2374.
35. Osek J, Jonson G, Svennerholm AM & Holmgren J (1994) Role of antibodies against biotype-specific Vibrio choleraepili in protection against experimental classical and El Tor cholera. Infect Immun 62: 2901-2907.
36. Patel SM, Rahman MA, Mohasin M et al. (2012) Memory B cell responses to Vibrio cholerae O1 lipopolysaccharide are associated with protection against infection from household contacts of patients with cholera in Bangladesh. Clin Vaccine Immunol 19: 842-848.
37. Paulovicová E, Korcová J, Farkas P & Bystrický S (2010) Immunological efficacy of glycoconjugates derived from Vibrio cholerae O1 serotype Ogawa detoxified LPS in mice. J Med Microbiol 59(Pt 12): 1440-1448.
38. Peeters JM, Hazendonk TG, Beuvery EC & Tesser GI (1989) Comparison of four bi-functional reagents for coupling peptides to proteins and the effect of the three moieties on the immunogenicity of the conjugates. J Immunol Methods 120: 133-143.
39. Phalipon A, Tanguy M, Grandjean C, Guerreiro C, Bélot F, Cohen D, Sansonetti PJ & Mulard LA (2009) A synthetic carbohydrate-protein conjugate vaccine candidate against Shigella flexneri 2a infection. J Immunol 182: 2241-2247.
40. Picazo J, Ruiz-Contreras J, Casado-Flores J, Giangaspro E, García-de-Miguel MJ, Hernández-Sampelayo T, Otheo E & Méndez C (2012) Impact of introduction of conjugate vaccines in the vaccination schedule on the incidence of pediatric invasive pneumococcal disease requiring hospitalization in Madrid (2007-2011). Pediatr Infect Dis J [Epub ahead of print]
41. Polotsky VY, Robbins JB, Bryla D & Schneerson R (1994) Comparison of conjugates composed of lipopolysaccharide from Shigella flexneri type 2a detoxified by two methods and bound to tetanus toxoid. Infect Immun 62: 210-214.
42. Price GA & Holmes RK (2012) Evaluation of TcpF-A2-CTB chimera and evidence of additive protective efficacy of immunizing with TcpF and CTB in the suckling mouse model of Cholera. PLoS ONE 7: e42434.
43. Ren D, Xie H, Zhang W, Hassan F, Petralia RS, Yu S, Lim DJ & Gu XX (2011) Intranasal immunization of the combined lipooligosaccharide conjugates protects mice from the challenges with three serotypes of Moraxella catarrhalis. PLoS ONE 6: e29553.
44. Robbins JB, Schneerson R & Szu SC (1995) Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J Infect Dis 171: 1387-1398.
45. Saksena R, Ma X, Wade TK, Kovác P & Wade WF (2005) Effect of saccharide length on the immunogenicity of neoglycoconjugates from synthetic fragments of the O-SP of Vibrio cholerae O1, serotype Ogawa. Carbohydr Res 340: 2256-2269.
46. Sinclair D, Abba K, Zaman K, Qadri F & Graves PM (2011) Oral vaccines for preventing cholera. Cochrane Database Syst Rev 3: CD008603.
47. Talaga P, Vialle S & Moreau M (2002) Development of a high-performance anion-exchange chromatography with pulsed-amperometric detection based quantification assay for pneumococcal polysaccharides and conjugates. Vaccine 20: 2474-2484.
48. Taylor RK, Kirn TJ, Meeks MD, Wade TK & Wade WF (2004) A Vibrio cholerae classical TcpA amino acid sequence induces protective antibody that binds an area hypothesized to be important for toxin-coregulated pilus structure. Infect Immun 72: 6050-6060.
49. Verez-Bencomo V, Fernández-Santana V, Hardy E et al. (2004) A synthetic conjugate polysaccharide vaccine against Haemophilus influenzae type b. Science 305: 522-525.
50. Villeneuve S, Souchon H, Riottot MM, Mazie JC, Lei P, Glaudemans CP, Kovác P, Fournier JM & Alzari PM (2000) Crystal structure of an anti-carbohydrate antibody directed against Vibrio cholerae O1 in complex with antigen: molecular basis for serotype specificity. P Natl Acad Sci USA 97: 8433-8438.
51. Wade WF (2011) Is a universal, one dose cholera vaccine possible? Open Vac J 4: 18-30.
52. Wade TK & Wade WF (2008) Variable gene family usage of protective and non-protective anti-Vibrio cholerae O1 LPS antibody heavy chains. Microbiol Immunol 52: 611-620.
53. Wade TK, Saksena R, Shiloach J, Kovac P & Wade WF (2006) Immunogenicity of synthetic saccharide fragments of Vibrio cholerae O1 (Ogawa and Inaba) bound to Exotoxin A. FEMS Immunol Med Microbiol 48: 237-251.
54. Wang J, Villeneuve S, Zhang J et al. (1998) On the antigenic determinants of the lipopolysaccharides of Vibrio cholerae O:1, serotypes Ogawa and Inaba. J Biol Chem 273: 2777-2783.
55. Xu P, Alam MM, Kalsy A, Charles RC, Calderwood SB, Qadri F, Ryan ET & Kováč P (2011) Simple, direct conjugation of bacterial O-SP-core antigens to proteins: development of cholera conjugate vaccines. Bioconjug Chem 22: 2179-2185.
56. Zhang J & Kovác P (1997) Synthesis of methyl alpha-glycosides of some higher oligosaccharide fragments of the O-antigen of Vibrio cholerae O1, serotype Inaba and Ogawa. Carbohydr Res 300: 329-339.